IDC005 🔍
: Highly aggressive tumors such as pancreatic cancer often feature extensive development of connective tissue, known as desmoplasia, and rapid growth of blood and lymphatic vessels, referred to as angiogenesis and lymph-angiogenesis. These processes are co-dependent. IDC005 is a bispecific antibody that targets desmoplasia and (lymph-)angiogenesis.
IDC007 🔍
: Systemic inflammatory response syndrome (SIRS) is a severe, often fatal cascade of exaggerated immune responses. It can be caused by infectious and autoimmune diseases such as COVID-19 and lupus, and immunotherapies like T-cell based therapies and immune checkpoint inhibitors. IDC007 is a bispecific antibody that suppresses two key molecules in the development of CRS.
IDC008 🔍
: More than 80% of cancer patients do not respond to treatment by immune checkpoint inhibitors, which is a challenge seen in tumors with severely immune-suppressed tumor microenvironment (TME). Another challenge is that some patients are susceptible to the drugs’ off-target adverse effects. IDC008 is a bispecific antibody that targets PAUF and an immune checkpoint molecule expressed in tumors. Targeting PAUF increases the selectivity of the immune checkpoint inhibition and alleviates TME immune suppression, at the same time.
Category
Pipeline
Indication
Development Stage
Monoclonal
Antibody
PBP1510
(Ulenistamab)
Pancreatic cancer,
Ovarian cancer
Monoclonal
Antibody
PBP1710
(Anti-CTHRC1)
Solid Tumors
Bispecific
Antibody
IDC001
Pancreatic cancer,
Ovarian cancer
Bispecific
Antibody
IDC002
Pancreatic cancer,
Ovarian cancer
Bispecific
Antibody
IDC003
Solid Tumors
Bispecific
Antibody
IDC004
Pancreatic cancer,
Ovarian cancer
Bispecific
Antibody
IDC005
Solid Tumors
Bispecific
Antibody
IDC007
Critical immune disorders
Bispecific
Antibody
IDC008
Pancreatic cancer,
Ovarian cancer
Bispecific
Antibody
IDC009
Pancreatic cancer,
Ovarian cancer
Bispecific
Antibody
IDC010
Immune diseases